Sanofi (SNY) Interest Coverage Ratio (2009 - 2026)
Sanofi's (SNY) quarterly Interest Coverage Ratio came in at 3.65 in Q2 2026, up 63.37% year-over-year from 2.23 in Q2 2025, and up 69.38% quarter-over-quarter from 11.92 in Q1 2026.
Analysis
Sanofi (SNY) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Sanofi has disclosed Interest Coverage Ratio across 18 years of filings, most recently posting 3.65 for Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 63.37% year-over-year to 3.65; the TTM figure through Jun 2026 stood at 3.58 (up 24.07% YoY), while the FY2025 annual figure was 11.27, up 266.72% from the prior year.
- Interest Coverage Ratio came in at 3.65 for Q2 2026 at Sanofi, up from 11.92 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 8.52 in Q4 2025 to a low of 27.24 in Q1 2022.
- Average Interest Coverage Ratio over 5 years is 10.37, with a median of 10.41 recorded in 2023.
- The largest YoY upside for Interest Coverage Ratio was 1695.54% in 2025 against a maximum downside of 118.43% in 2025.
- Over 5 years, Interest Coverage Ratio stood at 15.24 in 2022, then jumped by 64.68% to 5.38 in 2023, then surged by 90.08% to 0.53 in 2024, then surged by 1695.54% to 8.52 in 2025, then tumbled by 142.82% to 3.65 in 2026.
- Per Business Quant data, the three most recent Interest Coverage Ratio figures were 3.65 in Q2 2026, 11.92 in Q1 2026, and 8.52 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | - |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 10.28 |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 3.65 |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | -21.24 |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 1,199.14 |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 114.07 |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 52.24 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.65 |
| Mar 31, 2026 | -11.92 |
| Dec 31, 2025 | 8.52 |
| Sep 30, 2025 | -12.55 |
| Jun 30, 2025 | -9.96 |
| Mar 31, 2025 | -10.73 |
| Dec 31, 2024 | -0.53 |
| Sep 30, 2024 | -13.88 |
| Jun 30, 2024 | -4.56 |
| Mar 31, 2024 | -5.00 |
| Dec 31, 2023 | -5.38 |
| Sep 30, 2023 | -10.10 |
| Jun 30, 2023 | -9.20 |
| Mar 31, 2023 | -14.66 |
| Dec 31, 2022 | -15.24 |
| Sep 30, 2022 | -26.45 |
| Jun 30, 2022 | -14.18 |
| Mar 31, 2022 | -27.24 |
| Dec 31, 2021 | -18.01 |
| Sep 30, 2021 | -34.85 |